European Union drug regulator audits manufacturing site of Serum Institute

AstraZeneca Chief Executive (CEO) Pascal Soriot has indicated that the company may look at factories outside of the EU to meet the supply commitments.

After the UK drug regulator, it is learnt that the European Union (EU) drug regulator is also auditing the manufacturing site of Serum Institute of India (SII), which is making the Oxford-AstraZeneca Covid-19 vaccine.

A person in the know has told Business Standard that if the audit goes well, it can lead to SII supplying the vaccine to the UK as well as to the EU.

AstraZeneca has to deliver 180 million doses to the EU in the second quarter of the year and production constraints have cut down deliveries to the European countries. Recently, AstraZeneca Chief Executive (CEO) Pascal Soriot has